Nyxoah S.A.

NasdaqGM NYXH

Nyxoah S.A. Net Income Margin for the year ending December 31, 2023: -993.84%

Nyxoah S.A. Net Income Margin is -993.84% for the year ending December 31, 2023, a 1.84% change year over year. Net Income Ratio, also known as the profit margin, is the ratio of net income to net sales, showing the percentage of revenue that remains as profit after all expenses are deducted.

Nyxoah S.A. Net Income Margin for the year ending December 31, 2022 was -1,012.48%, a 68.77% change year over year.
Nyxoah S.A. Net Income Margin for the year ending December 31, 2021 was -3,241.67%, a 81.73% change year over year.
Nyxoah S.A. Net Income Margin for the year ending December 31, 2020 was -17,746.38%.

Key data

Date	Net Income Margin	EBITDA Margin	EBIT Margin	EBITDA

NasdaqGM: NYXH

Nyxoah S.A.

CEO	Mr. Olivier Taelman
IPO Date	April 28, 2021
Location	Belgium
Headquarters	Rue Edouard Belin 12
Employees	146
Sector	Health Care
Industries Pharmaceuticals Telehealth

Description

Nyxoah S.A., a medical technology company, focuses on the development and commercialization of solutions to treat sleep disordered breathing conditions. It offers Genio system, a CE-Marked, patient-centric, and hypoglossal neurostimulation therapy to treat moderate to severe obstructive sleep apnea. The company was incorporated in 2009 and is headquartered in Mont-Saint-Guibert, Belgium.

Key trends

Past 5 years